Literature DB >> 21481415

Natural history of hepatocellular adenoma formation in glycogen storage disease type I.

David Q Wang1, Laurie M Fiske, Caroline T Carreras, David A Weinstein.   

Abstract

OBJECTIVE: To characterize the natural history and factors related to hepatocellular adenoma (HCA) development in glycogen storage disease type Ia (GSD Ia). STUDY
DESIGN: Retrospective chart review was performed for 117 patients with GSD Ia. Kaplan-Meier analysis of HCA progression among two groups of patients with GSD Ia (5-year mean triglyceride concentration ≤ 500 mg/dL and >500 mg/dL); analysis of serum triglyceride concentration, body mass index SDS, and height SDS between cases at time of HCA diagnosis and age- and sex-matched control subjects.
RESULTS: Logrank analysis of Kaplan-Meier survival curve demonstrated a significant difference in progression to HCA between the 5-year mean triglyceride groups (P = .008). No significant difference was detected in progression to adenoma event between sexes. Serum triglyceride concentration was significantly different at time of diagnosis of adenoma (737 ± 422 mg/dL) compared with control subjects (335 ± 195 mg/dL) (P = .009). Differences in height SDS (P = .051) and body mass index SDS (P = .066) approached significance in our case-control analysis.
CONCLUSION: Metabolic control may be related to HCA formation in patients with GSD Ia. Optimizing metabolic control remains critical, and further studies are warranted to understand the pathogenesis of adenoma development.
Copyright © 2011 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21481415      PMCID: PMC3135733          DOI: 10.1016/j.jpeds.2011.02.031

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  19 in total

1.  Glycogen storage disease type I: diagnosis, management, clinical course and outcome. Results of the European Study on Glycogen Storage Disease Type I (ESGSD I).

Authors:  Jan Peter Rake; Gepke Visser; Philippe Labrune; James V Leonard; Kurt Ullrich; G Peter A Smit
Journal:  Eur J Pediatr       Date:  2002-08-22       Impact factor: 3.183

Review 2.  Hepatocellular adenomas in glycogen storage disease type I and III: a series of 43 patients and review of the literature.

Authors:  P Labrune; P Trioche; I Duvaltier; P Chevalier; M Odièvre
Journal:  J Pediatr Gastroenterol Nutr       Date:  1997-03       Impact factor: 2.839

3.  Glycogen disease of the liver (von Gierke's disease) with hepatomata; case report with metabolic studies.

Authors:  H H MASON; D H ANDERSEN
Journal:  Pediatrics       Date:  1955-12       Impact factor: 7.124

4.  Cornstarch therapy in type I glycogen-storage disease.

Authors:  Y T Chen; M Cornblath; J B Sidbury
Journal:  N Engl J Med       Date:  1984-01-19       Impact factor: 91.245

Review 5.  Glycogen storage disease type I: pathophysiology of liver adenomas.

Authors:  Philip J Lee
Journal:  Eur J Pediatr       Date:  2002-07-12       Impact factor: 3.183

6.  Effect of continuous glucose therapy with uncooked cornstarch on the long-term clinical course of type 1a glycogen storage disease.

Authors:  David A Weinstein; Joseph I Wolfsdorf
Journal:  Eur J Pediatr       Date:  2002-07-31       Impact factor: 3.183

Review 7.  Disturbed lipid metabolism in glycogen storage disease type 1.

Authors:  Robert H J Bandsma; G Peter A Smit; Folkert Kuipers
Journal:  Eur J Pediatr       Date:  2002-07-13       Impact factor: 3.183

Review 8.  Fanconi-Bickel syndrome--a congenital defect of facilitative glucose transport.

Authors:  R Santer; B Steinmann; J Schaub
Journal:  Curr Mol Med       Date:  2002-03       Impact factor: 2.222

Review 9.  Glycogen storage disease I and hepatocellular tumours.

Authors:  L Bianchi
Journal:  Eur J Pediatr       Date:  1993       Impact factor: 3.183

10.  Overexpression of fatty acid synthase in chemically and hormonally induced hepatocarcinogenesis of the rat.

Authors:  Matthias Evert; Regine Schneider-Stock; Frank Dombrowski
Journal:  Lab Invest       Date:  2005-01       Impact factor: 5.662

View more
  37 in total

1.  Tight metabolic control plus ACE inhibitor therapy improves GSD I nephropathy.

Authors:  Gyongyi O Okechuku; Lawrence R Shoemaker; Monika Dambska; Laurie M Brown; Justin Mathew; David A Weinstein
Journal:  J Inherit Metab Dis       Date:  2017-06-13       Impact factor: 4.982

2.  Multiple hepatic adenomas in a child with microvillus inclusion disease.

Authors:  Jennifer C Burgis; C Allan Pratt; John P T Higgins; John A Kerner
Journal:  Dig Dis Sci       Date:  2013-03-24       Impact factor: 3.199

3.  Sustained high plasma mannose less sensitive to fluctuating blood glucose in glycogen storage disease type Ia children.

Authors:  Hironori Nagasaka; Tohru Yorifuji; Robert H J Bandsma; Tomozumi Takatani; Hisaki Asano; Hiroshi Mochizuki; Mayuko Takuwa; Hirokazu Tsukahara; Ayano Inui; Tomoyuki Tsunoda; Haruki Komatsu; Eitaro Hiejima; Tomoo Fujisawa; Ken-Ichi Hirano; Takashi Miida; Akira Ohtake; Tadao Taguchi; Ichitomo Miwa
Journal:  J Inherit Metab Dis       Date:  2012-09-13       Impact factor: 4.982

4.  Long-term safety and efficacy of AAV gene therapy in the canine model of glycogen storage disease type Ia.

Authors:  Young Mok Lee; Thomas J Conlon; Andrew Specht; Kirsten E Coleman; Laurie M Brown; Ana M Estrella; Monika Dambska; Kathryn R Dahlberg; David A Weinstein
Journal:  J Inherit Metab Dis       Date:  2018-05-25       Impact factor: 4.982

5.  Gene therapy prevents hepatic tumor initiation in murine glycogen storage disease type Ia at the tumor-developing stage.

Authors:  Jun-Ho Cho; Young Mok Lee; Matthew F Starost; Brian C Mansfield; Janice Y Chou
Journal:  J Inherit Metab Dis       Date:  2019-03-06       Impact factor: 4.982

6.  Successful treatment of multiple hepatocellular adenomas with percutaneous radiofrequency ablation.

Authors:  Sun Young Ahn; Soo Young Park; Young Oh Kweon; Won Young Tak; Han Ik Bae; Seung Hyun Cho
Journal:  World J Gastroenterol       Date:  2013-11-14       Impact factor: 5.742

7.  Fenofibrate rapidly decreases hepatic lipid and glycogen storage in neonatal mice with glycogen storage disease type Ia.

Authors:  Zollie A Yavarow; Hye-Ri Kang; Lauren R Waskowicz; Boon-Huat Bay; Sarah P Young; Paul M Yen; Dwight D Koeberl
Journal:  Hum Mol Genet       Date:  2020-01-15       Impact factor: 6.150

8.  Glycogen storage disease type Ia: linkage of glucose, glycogen, lactic acid, triglyceride, and uric acid metabolism.

Authors:  Sakine Sever; David A Weinstein; Joseph I Wolfsdorf; Reyhan Gedik; Ernst J Schaefer
Journal:  J Clin Lipidol       Date:  2012-08-30       Impact factor: 4.766

9.  Safety and Efficacy of Chronic Extended Release Cornstarch Therapy for Glycogen Storage Disease Type I.

Authors:  Katalin M Ross; Laurie M Brown; Michelle M Corrado; Tayoot Chengsupanimit; Latravia M Curry; Iris A Ferrecchia; Laura Y Porras; Justin T Mathew; David A Weinstein
Journal:  JIMD Rep       Date:  2015-08-25

Review 10.  Lessons from new mouse models of glycogen storage disease type 1a in relation to the time course and organ specificity of the disease.

Authors:  Fabienne Rajas; Julie Clar; Amandine Gautier-Stein; Gilles Mithieux
Journal:  J Inherit Metab Dis       Date:  2014-08-28       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.